A Long Term Study of GK530G in Subjects With Acne Vulgaris
NCT ID: NCT01910064
Last Updated: 2017-03-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
436 participants
INTERVENTIONAL
2013-05-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
NCT02073448
Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris
NCT07345390
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
NCT02073461
Trial to Investigate GZ21T in Healthy Volunteers
NCT06888362
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
NCT06403501
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GK530G
GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
GK530G
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GK530G
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those with clinical diagnosis of acne vulgaris with more than 20 non-inflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).
Exclusion Criteria
* Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne.
* Those who have clinically significant abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to Investigator's judgment
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma investigational site
Urayasu, Chiba, Japan
Galderma investigational site
Fukuoka, Fukuoka, Japan
Galderma investigational site
Kawasaki, Kanagawa, Japan
Galderma investigational site
Yamato, Kanagawa, Japan
Galderma investigational site
Yokohama, Kanagawa, Japan
Galderma investigational site
Kumagaya, Saitama, Japan
Galderma investigational site
Chiyoda City, Tokyo, Japan
Galderma investigational site
Koto, Tokyo, Japan
Galderma investigational site
Machida, Tokyo, Japan
Galderma investigational site
Musashino, Tokyo, Japan
Galderma investigational site
Ōta-ku, Tokyo, Japan
Galderma investigational site
Shibuya City, Tokyo, Japan
Galderma investigational site
Shinjuku, Tokyo, Japan
Galderma investigational site
Suginami, Tokyo, Japan
Galderma investigational site
Tachikawa, Tokyo, Japan
Galderma investigational site
Kōtō City, Tpkyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RDT.07.SPR.27125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.